[HTML][HTML] Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro, E Felip - Translational Lung Cancer …, 2019 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
[PDF][PDF] Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro, E Felip - cdn.amegroups.cn
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro… - Translational Lung Cancer …, 2019 - tlcr.amegroups.org
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.
A Martinez-Marti, A Navarro, E Felip - Translational Lung Cancer …, 2019 - europepmc.org
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro… - … lung cancer research, 2019 - pubmed.ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
[HTML][HTML] Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
A Martinez-Marti, A Navarro… - Translational Lung Cancer …, 2019 - tlcr.amegroups.org
The epidermal growth factor receptor (EGFR) oncogene was positioned as an attractive
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …
target for drug development in non-small cell lung cancer (NSCLC). Gefitinib and erlotinib …